DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
A phase 2 trial of DZD8586 in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.
Overview
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) is a phase 2 interventional study registered as NCT06539182 by Dizal Pharmaceuticals, with 155 participants planned, started 2024-04-29 and due to reach its primary completion in 2027-09. Interventions recorded: DZD8586.
Similar pages
not linked directly; found by shared links- TrialA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Shares DZD8586, Dizal Pharmaceutical, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Shares DZD8586, Dizal Pharmaceutical, Chronic lymphocytic leukaemia.
- TrialA Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialDZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Shares DZD8586, Dizal Pharmaceutical.
- TrialA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialAssessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialA Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Shares Chronic lymphocytic leukaemia and the tag pipeline.